The Molecular Evolution of Castration-resistant Prostate Cancer.

Ceder, Yvonne; Bjartell, Anders; Culig, Zoran; Rubin, Mark A; Tomlins, Scott; Visakorpi, Tapio

Ceder, Yvonne; Bjartell, Anders; Culig, Zoran; Rubin, Mark A; Tomlins, Scott; Visakorpi, Tapio.

Afiliação

Ceder Y; Department of Laboratory Medicine, Division of Translational Cancer Research, Lund University, Lund, Sweden. Electronic address: yvonne.ceder@med.lu.se.
Bjartell A; Department of Translational Medicine, Division of Urological Cancers, Lund University, Malmö, Sweden.
Culig Z; Experimental Urology, Department of Urology, Medical University of Innsbruck, Innsbruck, Austria.
Rubin MA; Caryl and Israel Englander Institute for Precision Medicine, New York Presbyterian Hospital-Weill Cornell Medicine and Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
Tomlins S; Michigan Center for Translational Pathology, Department of Pathology, Department of Urology, University of Michigan Medical School, Ann Arbor, MI, USA.
Visakorpi T; Prostate Cancer Research Center, Institute of Biosciences and Medical Technology, University of Tampere and Tampere University Hospital, Tampere, Finland.

Eur Urol Focus ; 2(5): 506-513, 2016 Dec.

Article em En | MEDLINE | ID: mdl-28723516

Palavras-chave

Androgen deprivation therapy; Androgen receptor; Androgen synthesis; Castration-resistant prostate cancer; Prostate cancer

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Eur Urol Focus Ano de publicação: 2016 Tipo de documento: Article País de publicação: Holanda

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google